Background A significant subset of prostate cancer (PC) patients with a castration-resistant
form of the disease (CRPC) show primary resistance to androgen receptor (AR)-targeting …

PURPOSE Androgen receptor splice variant 7 (AR-V7) detection in circulating tumor cells
(CTCs) is associated with a low probability of response and short progression-free (PFS) …

Background There are multiple existing and emerging therapeutic avenues for metastatic
prostate cancer, with a common denominator, which is the need for predictive biomarkers …

Background Treatment of poor prognosis metastatic castration-resistant prostate cancer
(mCRPC) includes taxane chemotherapy and androgen receptor pathway inhibitors (ARPI) …

Circulating tumor DNA (ctDNA) has recently emerged as a minimally invasive “liquid biopsy”
tool in precision medicine. ctDNA-genomic DNA fragments that are released into the …

The new-generation hormonal agent enzalutamide has been approved for the treatment of
metastatic castration-resistant prostate cancer (CRPC), in both post-and predocetaxel …

PURPOSE Despite decreased screening-based detection of clinically insignificant tumors,
most diagnosed prostate cancers are still indolent, indicating a need for better strategies for …

PURPOSE Two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and rucaparib)
are US Food and Drug Administration–approved for patients with metastatic castration …

Purpose: DNA mismatch repair defects (MMRd) and tumor hypermutation are rare and
under-characterized in metastatic prostate cancer (mPC). Furthermore, because …

Background Better blood tests to elucidate the behaviour of metastatic castration-resistant
prostate cancer (mCRPC) are urgently needed to drive therapeutic decisions. Plasma cell …